GENinCode Plc Highlights CARDIO inCode-Score at European Society of Cardiology Congress

During the European Society of Cardiology Preventive Cardiology Congress in Athens, GENinCode Plc presented a study on the CARDIO inCode-Score. The research, conducted by Kaiser Permanente, assessed the risk of coronary heart disease (CHD) across a multi-ethnic cohort of 48,881 using both low-density lipoprotein cholesterol (LDL-C) and polygenic risk factors.

The study, which focused on the Northern California Genetic Epidemiology Resource in Adult Health and Aging (GERA), found that LDL-C and polygenic risk independently correlated with CHD incidence. Interestingly, the CARDIO inCode-Score effectively pinpointed individuals at highest CHD risk regardless of their LDL-C levels. The findings suggest that individuals with high polygenic risks benefit more from lipid-lowering therapies and those with high CARDIO inCode-Scores should maintain LDL-C levels below 130 mg/dL to minimize risk.

This presentation supports earlier research published in the American Journal of Preventive Cardiology, advocating for prioritized lifestyle and therapeutic interventions for those with high genetic risks. The inclusion of polygenic risk scores in lifetime risk assessments, alongside traditional methods, may enhance preventive strategies for CHD, particularly as cardiovascular diseases remain leading causes of death globally.